MediWound (MDWD) Projected to Post Quarterly Earnings on Thursday

MediWound (NASDAQ:MDWD) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.7067) per share and revenue of $6.73 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). The firm had revenue of $3.09 million during the quarter, compared to analyst estimates of $2.59 million. MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. On average, analysts expect MediWound to post ($2.37) EPS for the current fiscal year and ($2.30) EPS for the next fiscal year.

MediWound Stock Performance

Shares of MDWD opened at $14.11 on Wednesday. The company has a market capitalization of $183.57 million, a price-to-earnings ratio of -7.84 and a beta of 0.07. The company’s 50 day simple moving average is $13.19 and its 200 day simple moving average is $15.12. MediWound has a 1 year low of $11.80 and a 1 year high of $19.70.

Insider Activity at MediWound

In other news, COO Shmuel Hess sold 3,958 shares of the company’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 9.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

MDWD has been the subject of several recent analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 target price (down from $32.00) on shares of MediWound in a research note on Friday, August 14th. Wall Street Zen raised MediWound from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 26th. TD Cowen reissued a “buy” rating on shares of MediWound in a research note on Thursday, September 24th. Weiss Ratings cut MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Finally, Alliance Global Partners restated a “buy” rating on shares of MediWound in a report on Wednesday, September 16th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $33.00.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds. MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.